Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Type 2 diabetes mellitus (T2DM) can impaire cognitive function,the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.Cognitive impairment seriously affects the health and quality of life of the elderly. Prevention and treatment measures for cognitive decline in persons with T2DM has not been well studied.
Glucagon-like peptide-1 (GLP-1) is a member of an endogenous class of incretin hormones synthesized in intestinal epithelial L-cells.GLP-1 enhances glucose-dependent secretion of insulin,inhibits glucagon secretion, slows gastric emptying and reduces food intake. Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM. The effect on BMI,waist circumference, hip circumference, waist-to-hip ratio,fasting plasma glucose，glycosylated hemoglobin,blood lipids and cognitive function were measured to explore the effects of liraglutide in patients with T2DM.
The overall goal of this study is to explore the effects of liraglutide on the cognitive function in patients with type 2 diabetes mellitus and make further contribution to the improvement of cognitive function.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Liraglutide | Active Comparator | 12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide |
|
| Placebo | Placebo Comparator | 12 weeks of Placebo treatment at adjusting dose Drug:Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Liraglutide | Drug | Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of cognitive function assessed by cognitive function scale after 12 weeks. | The cognitive function will be calculated from performance on the following measures: (1)Digit Span Test(DST);(2) Rey Auditory Verbal Learning(RAVL);(3) Long-Delay Free Recall(LDFR);(4) Trail Making Test(TMT);(5) Animal Naming Test(ANT);(6) Clock Drawing Test(CDT);(7)Minimum Mental State Examination(MMSE);(8)Memory and executive screening(MES);(8)functional near-infrared spectroscopy. | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of systolic blood pressure and diastolic blood pressure | Change of systolic blood pressure and diastolic blood pressure compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of fasting plasma glucose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The third hospital affiliated to the Third Military Medical University | Chongqing | Chongqing Municipality | 400042 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34250817 | Derived | Li Q, Jia M, Yan Z, Li Q, Sun F, He C, Li Y, Zhou X, Zhang H, Liu X, Bu X, Gao P, He H, Zhao Z, Zhu Z. Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway. J Am Heart Assoc. 2021 Jul 20;10(14):e020734. doi: 10.1161/JAHA.120.020734. Epub 2021 Jul 10. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069450 | Liraglutide |
| ID | Term |
|---|---|
| D052216 | Glucagon-Like Peptide 1 |
| D004763 | Glucagon-Like Peptides |
| D052336 | Proglucagon |
| D005768 | Gastrointestinal Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| placebo | Drug | Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue. |
|
Change of fasting plasma glucose compared with baseline, and between the intervention and control group at the end of the study (12 weeks) |
| Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of HbA1c | Change of HbA1c compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of lipid profile | Change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of liver enzymes | Change of liver enzymes (ALT, AST in IU/L) compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of kidney function | Change of kidney function（serum creatinine in umol/L、eGFR in ml/min） compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of CRP | Change of CRP compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of Body mass index(BMI) | Change of Body mass index(BMI) compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of waist circumference | Change of waist circumference compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of hip circumference | Change of hip circumference compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| Change of waist-to-hip ratio | Change of waist-to-hip ratio compared with baseline, and between the intervention and control group at the end of the study (12 weeks) | Baseline,4weeks,8weeks，12weeks(End of Trial) |
| D004700 | Endocrine System Diseases |
| D006728 |
| Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |